Background and Aims: The prospective, observational Swiss Eosinophilic Esophagitis Cohort Study (SEECS) was set up in 2015 with the following goals in mind: (1) to provide up-to-date epidemiologic data; (2) to assess the appropriateness of care; (3) to evaluate the psychosocial impact; and (4) to foster translational research projects. Data capture relies on validated instruments to assess disease activity and focuses on epidemiologic variables and biosamples (esophageal biopsies and blood specimens). An annual inclusion of 70 new patients with eosinophilic esophagitis (EoE) or proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is intended. We herein describe the SEECS cohort profile. Methods: The SEECS includes adult patients (age ≥18 years) with EoE or PPI-REE diagnosed according to published criteria. After inclusion, the patients are typically seen once a year for a clinical and endoscopic/histologic follow-up examination. Data are captured using validated questionnaires. Biosamples from patients with gastroesophageal reflux disease (GERD) and controls with a healthy esophagus are collected as well. Results: From January 2016 to July 2017, a total of 111 patients with EoE and 10 patients with PPI-REE were recruited. In addition, esophageal biopsies and blood samples from 11 patients with GERD and 20 controls with a healthy esophagus were collected. The mean age of the patients with EoE and those with PPI-REE was 39.6 ± 12.9 and 44.6 ± 15.6 years, respectively. A male predominance was found among both the patients with EoE (77.5%) and those with PPI-REE (70%). Concomitant allergic disorders were found in 79.3% of the patients with EoE and 90% of the patients with PPI-REE. At inclusion, the EoE patients were treated with the following therapeutic regimens: no therapy (0.9%), PPI (36%), swallowed topical corticosteroids (82.9%), elimination diets (15.3%), and esophageal dilation (19.8%). Conclusions: The SEECS is the first national cohort study of patients with EoE or PPI-REE. The SEECS will provide up-to-date epidemiologic data and foster translational research projects.

1.
Attwood SE, Smyrk TC, Demeester TR, Jones JB: Esophageal eosinophilia with dysphagia, a distinct clinicopathologic syndrome. Dig Dis Sci 1993; 38: 109–116.
2.
Straumann A, Spichtin HP, Bernoulli R, et al: Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings (in German with English abstract). Schweiz Med Wochenschr 1994; 124: 1419–1429.
3.
Liacouras CA, Furuta GT, Hirano I, et al: Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3–20.
4.
Lucendo AJ, Molina-Infante J, Arias Á, et al: Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017; 5: 335–358.
5.
Dellon ES, Gonsalves N, Hirano I, et al: ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013; 108: 679–692.
6.
Furuta GT, Katzka DA: Eosinophilic esophagitis. N Engl J Med 2015; 373: 1640–1648.
7.
Spergel JM, Brown-Whitehorn T, Beausoleil JL, et al: Predictive values for skin prick test and atopy patch test for eosinophilic esophagitis. J Allergy Clin Immunol 2007; 119: 509–511.
8.
Straumann A, Spichtin HP, Grize L, et al: Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660–1669.
9.
Moawad FJ, Schoepfer AM, Safroneeva E, et al: Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. Aliment Pharmacol Ther 2014; 39: 603–608.
10.
Molina-Infante J, Bredenoord AJ, Chang E, et al: Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 2016; 65: 524–531.
11.
Assa’ad AH, Putnam PE, Collins MH, et al: Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol 2007; 119: 731–738.
12.
Helou EF, Simonson J, Arora AS: 3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. Am J Gastroenterol 2008; 103: 2194–2199.
13.
Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al: 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 48: 30–36.
14.
Kagalwalla AF, Akhtar N, Woodruff SA, et al: Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol 2012; 129: 1387–1396.
15.
Schoepfer AM, Safroneeva E, Bussmann C, et al: Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013; 145: 1230–1236.
16.
Lipka S, Kumar A, Richter JE: Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol 2016; 50: 134–140.
17.
Dellon ES, Kim HP, Sperry SL, et al: A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 2014; 79: 577–585.
18.
Taft TH, Kern E, Kwiatek MA, et al: The Adult Eosinophilic Oesophagitis Quality of Life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther 2011; 34: 790–798.
19.
Safroneeva E, Coslovsky M, Kuehni CE, et al: Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther 2015; 42: 1000–1010.
20.
Schoepfer AM, Hirano I, Katzka DA: Eosinophilic esophagitis: overview of clinical management. Gastroenterol Clin North Am 2014; 43: 329–344.
21.
Schoepfer A, Safroneeva E, Straumann A: How to measure disease activity in eosinophilic esophagitis. Dis Esophagus 2016; 29: 959–966.
22.
Schoepfer A, Straumann A, Panczak R, et al: Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology 2014; 147: 1255–1266.e21.
23.
Dellon ES, Irani AM, Hill MR, Hirano I: Development and field-testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther 2013; 38: 634–642.
24.
Patrick DL, Burke LB, Powers JH, et al: Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10(suppl 2):S125–S137.
25.
Hirano I, Moy N, Heckman MG, et al: Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013; 62: 489–495.
26.
Collins MH, Martin LJ, Alexander ES, et al: Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus 2017; 30: 1–8.
27.
Hruz P, Straumann A, Bussmann C, et al: Escalating incidence and prevalence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol 2011; 128: 1349–1350.
28.
Giriens B, Yan P, Safroneeva E, et al: Escalating incidence and prevalence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993–2013: a population-based study. Allergy 2015; 70: 1633–1639.
29.
Pittet V, Juillerat P, Mottet C, et al: Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009; 38: 922–931.
30.
Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES: Eosinophilic esophagitis: what can we learn from Crohn’s disease? United European Gastroenterol J 2017; 5: 762–772.
31.
Safroneeva E, Straumann A, Coslovsky M, et al: Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology 2016; 150: 581–590.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.